Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia-Reference-Cited by-同舟云学术

Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia

Published:2013-09-03 Issue:10 Volume:88 Page:858-861
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Mahévas Matthieu¹²,Ebbo Mikael³,Audia Sylvain⁴,Bonnotte Bernard⁴,Schleinitz Nicolas³,Durand Jean-Marc³,Chiche Laurent³,Khellaf Medhi¹,Bierling Philippe¹²,Roudot-Thoraval Françoise⁵,Godeau Bertrand¹,Michel Marc¹

Affiliation:

1. Department of Internal Medicine, Centre de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris; Université Paris Est Créteil; Créteil France

2. Etablissement Français du Sang Ile de France, Inserm U955, Créteil, Hôpital Henri Mondor; Paris France

3. Department of Internal Medicine; Hôpital de La Conception, Assistance publique-Hôpitaux de Marseille; Marseille France

4. Department of Internal Medicine; Hôpital universitaire Dijon; France

5. Department of Public Health, Hôpital Henri-Mondor; Université Paris Est Créteil; France

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23518/fullpdf

Reference19 articles.

1. B-cell targeting in rheumatoid arthritis and other autoimmune diseases;Edwards;Nat Rev Immunol,2006

2. B cell immunobiology in disease: Evolving concepts from the clinic;Martin;Annu Rev Immunol,2006

3. How I treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second-line treatment;Ghanima;Blood,2012

4. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study;Godeau;Blood,2008

5. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: A meta-analysis;Auger;Br J Haematol,2012

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Immune Thrombocytopenia: Contextualization from a Historical Perspective;Hematology Reports;2024-06-26

2. Lymphocyte subpopulations: a potential predictor of a response in patients with immune thrombocytopenia;Hematology;2024-01-22

3. Guidelines for the diagnosis and management of idiopathic thrombocytopenic purpura;Russian journal of hematology and transfusiology;2023-12-28

4. Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study;Platelets;2023-04-27

5. Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months;British Journal of Haematology;2023-04-20